Scholar Rock (SRRK) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
4 Jun, 2026Opening remarks and agenda
Meeting called to order and conducted virtually, welcoming stockholders and guests.
Meeting held in accordance with bylaws and Delaware law, with formal business and Q&A phases outlined.
Agenda and rules of conduct provided to all participants, with instructions for submitting questions.
Board and executive committee updates
Directors and management team introduced, including key officers and outside counsel.
Board members present included the CEO, President of R&D, and several independent directors.
Corporate governance
Inspector of Elections appointed to oversee voting and quorum confirmed with over 114 million shares represented.
Voting procedures explained, allowing proxy and virtual ballot submissions.
Nominations for Class II directors closed with four current board members nominated for three-year terms.
Latest events from Scholar Rock
- Apitegromab BLA accepted by FDA; strong cash reserves support global launch readiness.SRRK
Q1 202622 Jun 2026 - Apitegromab targets broad SMA eligibility, with global launch expected in 2026 and pipeline expansion ahead.SRRK
Goldman Sachs 47th Annual Global Healthcare Conference 20269 Jun 2026 - Dual-path regulatory strategy positions apitegromab for imminent global launch and strong growth.SRRK
Jefferies Global Healthcare Conference 20263 Jun 2026 - First myostatin inhibitor for SMA nears launch, backed by strong demand and financial stability.SRRK
Bank of America Global Healthcare Conference 202612 May 2026 - 2026 launches are on track, with strong liquidity and managed regulatory and supply risks.SRRK
Q4 20251 May 2026 - Virtual meeting to elect directors, ratify auditor, and approve executive pay, with strong governance.SRRK
Proxy filing23 Apr 2026 - Key votes include director elections, auditor ratification, and executive pay approval.SRRK
Proxy filing23 Apr 2026 - BLA resubmission for Apitegromab offers dual approval paths and strong launch readiness.SRRK
Status update31 Mar 2026 - Apitegromab targets a 2026 U.S. launch after regulatory delays, with global expansion and strong financials.SRRK
Leerink Global Healthcare Conference 202628 Mar 2026